Voyager Therapeutics (VYGR) EBIAT (2016 - 2025)
Historic EBIAT for Voyager Therapeutics (VYGR) over the last 11 years, with Q3 2025 value amounting to -$27.9 million.
- Voyager Therapeutics' EBIAT fell 20840.34% to -$27.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$126.8 million, marking a year-over-year decrease of 58988.41%. This contributed to the annual value of -$65.0 million for FY2024, which is 14912.11% down from last year.
- As of Q3 2025, Voyager Therapeutics' EBIAT stood at -$27.9 million, which was down 20840.34% from -$33.4 million recorded in Q2 2025.
- In the past 5 years, Voyager Therapeutics' EBIAT ranged from a high of $124.0 million in Q1 2023 and a low of -$34.5 million during Q4 2024
- Its 5-year average for EBIAT is -$7.5 million, with a median of -$21.6 million in 2021.
- Its EBIAT has fluctuated over the past 5 years, first plummeted by 51383.78% in 2022, then soared by 68184.72% in 2023.
- Over the past 5 years, Voyager Therapeutics' EBIAT (Quarter) stood at $5.7 million in 2021, then plummeted by 513.84% to -$23.6 million in 2022, then skyrocketed by 338.7% to $56.4 million in 2023, then crashed by 161.15% to -$34.5 million in 2024, then increased by 19.12% to -$27.9 million in 2025.
- Its last three reported values are -$27.9 million in Q3 2025, -$33.4 million for Q2 2025, and -$31.0 million during Q1 2025.